Gordon Hamilton is the CEO of PicoSeq, a Paris-based company he co-founded in 2012. The company is developing a novel single-molecule technology for genetic and epigenetic analysis. Prior to PicoSeq he worked as Medical Director of ChemoCentryx Inc, a Californian biotechnology company, where he worked on clinical-phase development of small molecule therapeutics targeting the chemokine system. He has also worked as a physician in the National Health Service. He has a Master’s degree in Physiological Sciences from the University of Oxford, a medical degree from Imperial College School of Medicine, and an MBA from INSEAD.